Isosorbide Use Guidelines

Key Considerations for Isosorbide Administration

• When combined with hydralazine, careful monitoring is warranted in patients with cardiovascular disease, as hydralazine can cause reflex tachycardia 1
• The American College of Cardiology and American Heart Association specify isosorbide dinitrate use in patients ≥18 years of age for heart failure with reduced ejection fraction, with no upper age limit for isosorbide use 2, 3, 4, 5
• For Black or African American patients with NYHA class III-IV HFrEF on optimal therapy, the hydralazine/isosorbide dinitrate combination is a Class 1 recommendation to reduce morbidity and mortality 3, 4, 5
• Isosorbide dinitrate lacks established pediatric safety profiles and dosing guidelines, and the American Academy of Pediatrics does not include it in recommended treatment algorithms for children 6
• Hold or avoid isosorbide in pediatric patients due to absence of evidence 6
• Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) is an absolute contraindication for isosorbide use 5
• Hypertrophic cardiomyopathy with outflow obstruction is an absolute contraindication for isosorbide use 5
• Severe anemia (may worsen tissue hypoxia) is a relative contraindication requiring assessment 5
• A nitrate-free interval of at least 10-12 hours daily is essential to prevent complete loss of anti-ischemic effects 7